E
Enveric Biosciences, Inc. (ENVB)
NCM – Real Time Price. Currency in USD
2.52
-0.29 (-10.32%)
At close: May 12, 2026, 4:00 PM EDT
2.60
+0.08 (3.12%)
After-hours: May 12, 2026, 7:55 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
2.52
-0.29 (-10.32%)
At close: May 12, 2026, 4:00 PM EDT
2.60
+0.08 (3.12%)
After-hours: May 12, 2026, 7:55 PM EDT
Enveric Biosciences, Inc., a biotechnology company, focuses on the development of small molecule neuroplastogenic therapeutics that address unmet needs in psychiatric and neurological disorders in the United States. Its lead drug candidate is EB-003, a novel derivative of DMT in preclinical development for mental health indications. The company also develops EVM401 series comprising novel phenylalkylamines and indolethylamines, as well as mescaline-derived compounds to target addiction and neuropsychiatric disorders; and Psybrary, a proprietary library. Enveric Biosciences, Inc. is headquartered in Cambridge, Massachusetts.
| Name | Position |
|---|---|
| Dr. Joseph Edward Tucker Ph.D. | CEO & Director |
| Dr. Peter J. Facchini Ph.D. | Chief Innovation Officer |
| Mr. Kevin M. Coveney CPA | Chief Financial Officer |
| Date | Type | Document |
|---|---|---|
| 2026-05-04 | D | |
| 2026-04-30 | 8-K | form8-k.htm |
| 2026-04-23 | S-3 | forms-3.htm |
| 2026-04-20 | 8-K | form8-k.htm |
| 2026-04-14 | DEF 14A | formdef14a.htm |
| 2026-04-14 | ARS | formars.pdf |
| 2026-04-03 | PRE 14A | formpre14a.htm |
| 2026-03-27 | 8-K | form8-k.htm |
| 2026-02-11 | D | |
| 2026-02-10 | S-1 | forms-1.htm |